Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistance
Cancer Drug Resistance · 21.04.2026
DOI: 10.20517/cdr.2025.207 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 21.04.2026. Verfasst von Yiyang Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Northeastern University, Boston, MA 02108, USA. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune-checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have substantially improved outcomes for patients with multiple cancer types; however, primary (intrinsic) resistance remains common and limits durable responses. Mechanistically, such resistance can arise from impaired interferon-γ signaling (including Janus kinases-signal transducer and activator of transcription dysfunction), tumor-intrinsic oncogenic pathway alterations [e.g., phosphatase and tensin homolog (PTEN) loss with downstream phosphoinositide 3-kinase/protein kinase B hyperactivation and Wnt/β-catenin-associated immune escape], and tumor-extrinsic immunosuppression mediated by PD-L1-upregulated suppressive myeloid populations such as myeloid-derived suppressor cells. These pathways converge on reduced T-cell effector function, compromised immune recognition, and reinforcement of an immunosuppressive tumor microenvironment (TME), collectively diminishing the clinical benefit of PD-1/PD-L1 blockade. In this review, we synthesize current evidence on primary (intrinsic) resistance to PD-1/PD-L1 blockade and discuss how nanomaterial-enabled interventions can be mechanistically matched to these resistance determinants. The nanotechnology-based therapeutic strategies were classified as four categories: (i) modulation of resistance-associated signaling pathways; (ii) direct blockade/interception of the PD-1/PD-L1 axis; (iii) immune-checkpoint gene silencing; and (iv) TME reprogramming.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering, Northeastern University, Boston, MA 02108, USA.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, Zhejiang, China.
- National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
Zitieren
APA
Lin, Y., & Shen, J. (2026). Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistance. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.207
Vancouver
Lin Y, Shen J. Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistance. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.207
BibTeX
@article{Lin2026,
author = {Lin, Yiyang and Shen, Jianliang},
title = {Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistance},
journal = {Cancer Drug Resistance},
year = {2026},
doi = {10.20517/cdr.2025.207}
}
EUVIMED